Cyclacel Pharmaceuticals (NASDAQ:CYCC) Issues Earnings Results, Beats Estimates By $0.36 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.36, Zacks reports. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Stock Down 11.7 %

Shares of NASDAQ:CYCC opened at $0.40 on Thursday. The business has a fifty day simple moving average of $0.88 and a 200 day simple moving average of $1.44. Cyclacel Pharmaceuticals has a 12-month low of $0.37 and a 12-month high of $6.00. The firm has a market cap of $854,625.00, a P/E ratio of -0.05 and a beta of 0.56.

Analysts Set New Price Targets

A number of brokerages have recently commented on CYCC. StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research note on Thursday, November 7th. They issued a “sell” rating for the company. Roth Capital downgraded Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.